• Home
  • » 
  • Reports
  • » 
  • Non-Invasive Diagnostics for Fibrotic Di...

Non-Invasive Diagnostics for Fibrotic Diseases

Non-Invasive Diagnostics for Fibrotic Diseases Market, 2020-2030: Focus on Liver, Pulmonary, Cystic and Other Types of Fibrosis

  • Lowest Price Guaranteed From USD 4,899

  • Published
    September 2020

  • Pages
    330

  • View Count
    4518

  • Buy Now

Example Insights

Non-Invasive-Diagnostics-for-Fibrotic-Disease-Market-Context Non-Invasive-Diagnostics-for-Fibrotic-Disease-Market-Fibrotic-Diseases Non-Invasive-Diagnostics-for-Fibrotic-Disease-Market-Affiliated-Biomarker
Non-Invasive-Diagnostics-for-Fibrotic-Disease-Market-Research-Landscape Non-Invasive-Diagnostics-for-Fibrotic-Disease-Market-Cloud-of-Biomarkers Non-Invasive-Diagnostics-for-Fibrotic-Disease-Market-Type-of-Patent
Non-Invasive-Diagnostics-for-Fibrotic-Disease-Market-Type-of-Partnership Non-Invasive-Diagnostics-for-Fibrotic-Disease-Market-End-User  

 

Report Description

The current market for non-invasive diagnostics for fibrotic diseases is expected to be worth $1.6 billion; it is likely to grow to $4.2 billion by 2030. With changing lifestyle and subsequently rising numbers of chronic ailments (such as obesity and diabetes), the prevalence of fibrotic diseases has also witnessed a surge globally. For instance, liver fibrosis is a common secondary pathological development observed in patients suffering from metabolic / cholestatic diseases, individuals consuming excessive quantities of alcohol and patients suffering from viral hepatitis. With non-alcoholic fatty liver disease (NAFLD) (subsequently progressing to nonalcoholic steatohepatitis / NASH) being the primary cause of liver disease, nearly 4.5 million adults in the US have been diagnosed with this condition in 2018. Similarly, idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, life-threatening interstitial lung disease reported in individuals with high exposure to deadly pollutants, radiation treatments and chemotherapeutic drugs. Although, IPF is a rare disease, nearly 40,000 new cases are diagnosed in the Europe, annually. Early diagnosis of fibrotic diseases is crucial to the condition being successfully managed / treated. However, timely diagnosis of this medical condition has been a known challenge due to the absence of overt symptoms. When symptoms appear, the patient suspected with the disease is suggested to undergo tissue biopsy for the disease confirmation. Considering that a tissue biopsy, a painful and traumatic procedure, is the currently accepted standard of diagnosis, there is a stigma associated with the process. Moreover, owing to the invasive nature of the test, it cannot be frequently repeated in order to monitor disease progress or validate therapeutic outcomes. There is, therefore, an established unmet need for a safer and more patient friendly diagnostic method.

Advances in the field of biotechnology have enabled the development of several minimally invasive / non-invasive approaches for diagnosis of fibrotic diseases which include imaging diagnostics and biomarker-based assays. Among the biomarker-based tests, liquid biopsy (based on the analysis of biofluids such as blood, urine and / or plasma), a relatively new concept, has emerged as a versatile and promising non-invasive cancer diagnostic method for the detection of not only cancer but also fibrosis. In addition, there are numerous forms of genetic analysis which enable accurate diagnosis of diseases such as cystic fibrosis; these biomarker and genetic tests are backed by clinical data, validating their relevance and applicability across several types of fibrotic indications, and are anticipated to replace the existing invasive diagnostic techniques in the future.

Scope of the Report

The “Non-Invasive Diagnostics for Fibrotic Disease Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these products over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of non-invasive diagnostics for fibrosis, providing information and analyses based on a number of relevant parameters, such as status of development (available or under development) of products, type of product (assay-kits, devices and software), application area (diagnostics, monitoring, screening and research), target fibrotic disease (cardiac fibrosis, cystic fibrosis, liver fibrosis, pulmonary fibrosis and renal fibrosis), type of sample (blood, saliva, mucus and buccal swab), type of biomarker, end user (hospitals / clinics, research institutes and self-tests), turnaround time and requirement of medical assistance. In addition, the chapter includes information on the device developers, including details on year of establishment, company size and location of headquarters.
  • Elaborate profiles of key players developing non-invasive diagnostics for fibrosis, featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and an informed future outlook.
  • An analysis of the partnerships that have been inked by stakeholders in this domain since 2016, distribution agreements, acquisitions, product development agreements, joint venture, licensing (specific to affiliated products), product utilization agreements, clinical trial agreements  product development and commercialization and others relevant types of deals. 
  • A detailed analysis of completed, ongoing and planned clinical studies for non-invasive diagnostics of fibrotic diseases, based on various relevant parameters, such as current trial status, trial registration year, phase of development, study design, study focus, product types, target fibrotic disease and enrolled patient population, highlighting leading sponsors, popular products and regional distribution of trials.
  • An insightful analysis of potential biomarkers for non-invasive diagnosis of liver fibrosis, taking into consideration biomarker type (physical / biological) and measurement indexes, highlighting leading sponsors involved in the clinical evaluation of biomarkers.
  • An in-depth analysis of over 13,000 patents that have been filed / granted for non-invasive diagnostics for fibrotic diseases, till May 2020, highlighting key trends associated with these patents, across type of patent, publication year and application year, regional applicability, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent benchmarking and valuation.  

One of the key objectives of the report was to estimate the existing market size and the future opportunity for non-invasive diagnostics for fibrotic diseases, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of non-invasive approaches for fibrotic diseases and their likely selling price, we have provided informed estimates on the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] target fibrotic disease (cystic fibrosis, liver fibrosis and pulmonary fibrosis) [B] end user (hospitals / clinics and research institutes) and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America and Middle East and North Africa). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

The opinions and insights presented in the report were also influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Garry de Jong (Chief Executive Officer, Repeat Diagnostics)
  • Herman Steen (Chief Executive Officer, Biorion)
  • Lawrence Cohen (Chief Executive Officer) and Charles Swindell (Chief Scientific Officer), Glycotest

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the state of the market for non-invasive diagnostics of fibrotic diseases, in the short-midterm and long term.

Chapter 3 provides a general overview of different types of fibrotic diseases and pathogenesis of the disease. In this section of the report, we have also highlighted the importance of early diagnosis and screening of the disease. The chapter outlines the conventional invasive diagnostic tests, which are widely used for diagnosis and prognosis, their limitations and the need / future opportunity of non-invasive approaches.

Chapter 4 presents information on different imaging techniques, screening assays and advanced approaches used for diagnosis of fibrosis, highlighting the advantages and disadvantages of each of the aforementioned techniques.

Chapter 5 includes information on more than 100 non-invasive products that are either developed or being developed for diagnosis of various fibrotic diseases. It features a detailed analysis of products, based on status of development (available or under development), type of products (assay-kits, devices and software), application area (diagnostics, monitoring, screening and research), target fibrotic disease (cardiac fibrosis, cystic fibrosis, liver fibrosis, pulmonary fibrosis and renal fibrosis), type of sample (blood, saliva, mucus and buccal swab), type of biomarker, end user (hospitals and clinics, research institutes and self-tests), turnaround time and requirement of medical assistance. In addition, the chapter provides information on product developer(s), and analysis based on year of their establishment, location of headquarters and employee strength.

Chapter 6 provides detailed profiles of some of the leading stakeholders in this field (shortlisted based on number of pipeline products). Each profile presents a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.

Chapter 7 features an in-depth analysis and discussion on the various partnerships that have been inked among players in this market, during the time period between 2016 and 2020 (till May). It also includes a brief description of the various types of partnership models (distribution
acquisition, product development, joint venture, licensing, product utilization, clinical trial  product development and commercialization and others) that have been adopted by stakeholders in this domain.

Chapter 8 provides a detailed analysis of more than 60 completed, ongoing and planned clinical studies for non-invasive diagnostics of fibrotic diseases, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors (in terms of number of trials conducted), study focus, product types, popular products, target fibrotic disease, enrolled patient population and regional distribution of trials.

Chapter 9 presents an insightful case study on biomarkers being evaluated for liver fibrosis, featuring analysis based on by type of biomarker and type of liver fibrosis, highlighting popular biomarkers and leading players (both industry and non-industry).

Chapter 10  includes an in-depth analysis of over 13,000 patents filed / granted for non-invasive diagnostic products for fibrotic diseases, highlighting key trends associated with these patents, across type of patent, publication year and application year, regional applicability, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent benchmarking and valuation.

Chapter 11 features a detailed market forecast analysis, highlighting the likely growth of market for non-invasive diagnostics for fibrotic diseases, till the year 2030. We have segmented the opportunity based on [A] target fibrotic disease (cystic fibrosis, lung fibrosis and pulmonary fibrosis), [B] end user (hospitals / clinics and research institutes) and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America and Middle East and North Africa). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

Chapter 12 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of non-invasive diagnostics for fibrotic diseases.

Chapter 13 is a collection of interview transcripts of discussions held with key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Gary de Jong (Chief Executive Officer, Repeat Diagnostics), Herman Steen (Chief Executive Officer, Biorion), Lawrence Cohen (Chief Executive Officer, Glycotest) and Charles Swindell (Chief Scientific Officer, Glycotest),

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 15 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Fibrosis
3.3. Diagnostics of Fibrosis
3.4. Conventional Invasive Fibrosis Diagnostic Tests
3.4.1. Biopsy
3.4.2. Endoscopy
3.4.3. Radiology
3.4.4. Limitations of Conventional Diagnostics and Need for Non-Invasive Methods

3.5. Non-Invasive Diagnostic Techniques
3.5.1. Diagnostic Biomarkers
3.5.1.1 Biomarkers for Diagnosis of Liver Fibrosis
3.5.1.2 Biomarkers for Diagnosis of Kidney Fibrosis
3.5.1.3 Biomarkers for Diagnosis of Pulmonary Fibrosis
3.5.1.4 Biomarkers for Diagnosis of Cardiac Fibrosis

3.5.2. Imaging / Scanning Devices

3.6. Conclusion

4. CONCEPT OF NON-INVASIVE FIBROSIS SCREENING AND DIAGNOSTICS
4.1. Chapter Overview
4.2. Imaging / Scanning Based Diagnostics
4.2.1. Computerized Tomography (CT) Scan
4.2.2. Integrated Positron Emission Tomography (PET) -CT Scan
4.2.3. Magnetic Resonance Imaging (MRI)
4.2.4. Ultrasound

4.3. Screening Assays
4.3.1. Biomarker Tests
4.3.2. Digital Rectal Exam (DRE)
4.3.3. Fecal Occult Blood Tests (FOBT)

4.4. Advanced Non-invasive Approaches
4.4.1. Cytogenetic / Gene Expression Studies
4.4.2. Liquid Biopsy
4.4.3. Optical Biopsy
4.4.4. Saliva-Based Oral Fibrosis Diagnostics
4.4.5. Vital Staining

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Non-Invasive Diagnostics for Fibrotic Diseases: Overall Market Landscape
5.2.1. Analysis by Status of Development
5.2.2. Analysis by Type of Product
5.2.3. Analysis by Application Area
5.2.4. Analysis by Target Fibrotic Disease
5.2.5. Analysis by Type of Product and Target Fibrotic Disease
5.2.6. Analysis by Type of Sample
5.2.7. Analysis by Type of Biomarker
5.2.8. Analysis by End User
5.2.9. Heat Map Analysis by Target Fibrotic Disease and End User
5.2.10. Analysis by Turnaround Time
5.2.11. Analysis by Requirement of Medical Assistance

5.4. Non-Invasive Diagnostics for Fibrotic Diseases: List of Developers
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size
5.4.3. Analysis by Geographical Location
5.4.4. Leading Developers: Analysis by Number of Products

6. COMPANY PROFILES
6.1. Chapter Overview

6.2. BioPredictive
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Non-Invasive Diagnostics Portfolio
6.2.4. Recent Developments and Future Outlook

6.3. Echosens
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Non-Invasive Diagnostics Portfolio
6.3.4. Recent Developments and Future Outlook

6.4. ELITechGroup
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Non-Invasive Diagnostics Portfolio
6.4.4. Recent Developments and Future Outlook

6.5. Fibronostics
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Non-Invasive Diagnostics Portfolio
6.5.4. Recent Developments and Future Outlook

6.6. Fujirebio
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Non-Invasive Diagnostics Portfolio
6.6.4. Recent Developments and Future Outlook

6.7. GenPath Diagnostics
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Non-Invasive Diagnostics Portfolio
6.7.4. Recent Developments and Future Outlook

6.8. HepQuant
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Non-Invasive Diagnostics Portfolio
6.8.4. Recent Developments and Future Outlook

6.9. LabCorp
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Non-Invasive Diagnostics Portfolio
6.9.4. Recent Developments and Future Outlook

6.10. Luminex
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Non-Invasive Diagnostics Portfolio
6.10.4. Recent Developments and Future Outlook

6.11. Oasis Diagnostics
6.11.1. Company Overview
6.11.2. Financial Information
6.11.3. Non-Invasive Diagnostics Portfolio
6.11.4. Recent Developments and Future Outlook

6.12. PerkinElmer
6.12.1. Company Overview
6.12.2. Financial Information
6.12.3. Non-Invasive Diagnostics Portfolio
6.12.4. Recent Developments and Future Outlook

6.13. Yourgene Health
6.13.1. Company Overview
6.13.2. Financial Information
6.13.3. Non-Invasive Diagnostics Portfolio
6.13.4. Recent Developments and Future Outlook

7. PARNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Non-Invasive Diagnostics for Fibrotic Diseases: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Product
7.3.4. Most Popular Products: Analysis by Number of Partnerships
7.3.5. Analysis by Target Fibrotic Disease
7.3.6. Analysis by Year of Partnership and Type of Partner
7.3.7. Analysis by Type of Partnership and Type of Partner
7.3.8. Most Active Players: Analysis by Number of Partnerships
7.4. Regional Analysis
7.4.1. Intercontinental and Intracontinental Agreements

8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology

8.3. Non-Invasive Diagnostics for Fibrotic Diseases: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Trial Recruitment Status
8.3.3. Analysis by Trial Registration Year and Number of Patients Enrolled
8.3.4. Analysis by Study Design
8.3.5. Analysis by Type of Sponsor / Collaborator
8.3.6. Leading Players: Analysis by Number of Registered Trials
8.3.7. Word Cloud: Key Focus Areas
8.3.8. Analysis by Target Fibrotic Disease
8.3.9. Popular Product Types: Analysis by Number of Registered Trials
8.3.10. Popular Products: Analysis by Number of Registered Trials 
8.3.11. Heat Map Analysis by Target Fibrotic Disease and Product Type
8.3.12. Geographical Analysis by Number of Registered Trials
8.3.13. Geographical Analysis by Number of Patients Enrolled

9. CASE STUDY: BIOMARKER ANALYSIS FOR LIVER FIBROSIS
9.1. Chapter Overview
9.2. Scope and Methodology

9.3. Non-Invasive Diagnostics for Fibrotic Diseases: Biomarker Analysis for Liver Fibrosis
9.3.1. Analysis by Type of Biomarker
9.3.2. Analysis by Trial Phase and Type of Biomarker
9.3.3. Analysis by Type of Liver Fibrosis
9.3.4. Popular Biomarkers: Analysis by Number of Registered Trials 
9.3.5. Heat Map Analysis by Popular Biomarkers and Trial Phase
9.3.6. Word Cloud Analysis: Popular and Emerging Biomarkers
9.3.7. Leading Players: Analysis by Number of Registered Trials
9.3.8. Heat Map Analysis by Popular Biomarkers and Leading Industry Players
9.3.9. Heat Map Analysis by Popular Biomarkers and Leading Non-industry Players

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology

10.3. Non-Invasive Diagnostics for Fibrotic Diseases: Patent Analysis
10.3.1. Analysis by Type of Patent
10.3.2. Analysis by Publication Year
10.3.3. Analysis by Issuing Authority / Patent Offices Involved
10.3.4. Analysis by CPC Symbols
10.3.5. Emerging Focus Areas
10.3.6. Leading Players: Analysis by Number of Patents

10.4. Non-Invasive Diagnostics for Fibrotic Diseases: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics

10.5. Non-Invasive Diagnostics for Fibrotic Diseases: Patent Valuation Analysis
10.6. Leading Patents by Number of Citations

11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Non-Invasive Diagnostics for Fibrotic Diseases Market, 2020-2030
11.4. Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by Target Fibrotic Disease
11.4.1. Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Cystic Fibrosis, 2020-2030
11.4.2. Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Liver Fibrosis, 2020-2030
11.4.3. Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Pulmonary Fibrosis, 2020-2030
11.5. Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by End User, 2020-2030
11.5.1. Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Hospitals, 2020-2030
11.5.2. Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Research Institutes, 2020-2030
11.6. Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by Region
11.6.1. Non-Invasive Diagnostics for Fibrotic Diseases Market in North America, 2020-2030
11.6.2. Non-Invasive Diagnostics for Fibrotic Diseases Market in Europe, 2020-2030
11.6.3. Non-Invasive Diagnostics for Fibrotic Diseases Market in Asia Pacific, 2020-2030
11.6.4. Non-Invasive Diagnostics for Fibrotic Diseases Market in Latin America, 2020-2030
11.6.5. Non-Invasive Diagnostics for Fibrotic Diseases Market in Middle East and North Africa, 2020-2030

12. CONCLUDING REMARKS
12.1. Chapter Overview
12.2. Key Takeaways

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview

13.2. Biorion
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Herman Steen, Chief Executive Officer, Biorion

13.3. Glycotest
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Lawrence Cohen, Chief Executive Officer and Charles Swindell, Chief Scientific Officer

13.4. Repeat Diagnostics
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Garry de Jong, Chief Executive Officer, Repeat Diagnostics

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Molecular Mechanism Involved in Fibrosis
Figure 3.2 Pathological Characteristics of Fibrosis in Different Organs
Figure 4.1 Non-Invasive Screening and Diagnosis of Fibrosis
Figure 4.2 Types of Diagnostic Imaging
Figure 4.3 Types of Screening Assays
Figure 4.4 Types of Advanced Non-Invasive Approaches
Figure 5.1 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Status of Development
Figure 5.2 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Type of Product
Figure 5.3 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Application Area
Figure 5.4 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Target Fibrotic Disease
Figure 5.5 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Type of Product and Target Fibrotic Disease
Figure 5.6 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Type of Sample
Figure 5.7 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Type of Biomarker
Figure 5.7 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by
Figure 5.8 Heat Map Analysis: Distribution by Target Fibrotic Disease and End User
Figure 5.9 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Turnaround Time
Figure 5.10 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Requirement of Medical Assistance
Figure 5.11 Product Developers: Distribution by Year of Establishment
Figure 5.12 Product Developers: Distribution by Company Size
Figure 5.13 Product Developers: Distribution by Geographical Location
Figure 5.14 Leading Developers: Distribution by Number of Products
Figure 6.1 BioPredictive: Annual Revenues, 2016-2020 (USD Billion)
Figure 6.2 Echosens: Annual Revenues, 2016-2019 (USD Billion)
Figure 6.3 ELITechGroup: Annual Revenues, 2016-2019 (USD Billion)
Figure 6.4 Fibronotics: Annual Revenues, 2016-2019 (USD Billion)
Figure 6.5 Fujirebio: Annual Revenues, 2016-2020 (USD Billion)
Figure 6.6 GenPath Diagnostics: Annual Revenues, 2016-2019 (USD Billion)
Figure 6.7 HepQuant: Annual Revenues, 2016-2019 (USD Billion)
Figure 6.8 LabCorp: Annual Revenues, 2016-2019 (USD Billion)
Figure 6.9 Luminex: Annual Revenues, 2016-2020 (USD Billion)
Figure 6.10 Oasis Diagnostics: Annual Revenues, 2016-2019 (USD Billion)
Figure 6.11 PerkinElmer: Annual Revenues, 2016-2020 (USD Billion)
Figure 6.12 Yourgene Health: Annual Revenues, 2016-2019 (USD Billion)
Figure 7.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Type of Product
Figure 7.4 Most Popular Products: Distribution by Number of Partnerships
Figure 7.5 Partnerships and Collaborations: Distribution by Target Fibrotic Disease
Figure 7.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 7.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 7.8 Most Active Players: Distribution by Number of Partnerships
Figure 7.9 Partnerships and Collaborations: Regional Analysis
Figure 7.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 8.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 8.2 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2020 (till June)
Figure 8.3 Clinical Trial Analysis: Cumulative Year-wise Trend in Number of Patients Enrolled, Pre-2010-2020 (till June)
Figure 8.4 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 8.5 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, Pre-2002-2020 (till June)
Figure 8.6 Clinical Trial Analysis: Distribution by Study Design
Figure 8.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.8 Leading Players: Analysis by Number of Trials
Figure 8.9 Word Cloud Analysis: Distribution by Focus Area
Figure 8.10 Clinical Trial Analysis: Distribution by Target Fibrotic Disease
Figure 8.11 Popular Product(s): Distribution by Number of Registered Trials
Figure 8.12 Popular Product Types: Distribution by Number of Registered Trials
Figure 8.13 Popular Product Types: Distribution by Status of Clinical Trials
Figure 8.14 Heat Map Analysis: Analysis by Target Fibrotic Disease and Type of Product
Figure 8.15 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 8.16 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 9.1 Biomarker Analysis for Liver Fibrosis: Scope and Methodology
Figure 9.2 Biomarker Analysis for Liver Fibrosis: Distribution by Type of Biomarker
Figure 9.3 Biomarker Analysis for Liver Fibrosis: Distribution by Trial Phase and Type of Biomarker
Figure 9.4 Biomarker Analysis for Liver Fibrosis: Distribution by Type of Liver Fibrosis
Figure 9.5 Popular Biomarkers: Distribution by Number of Registered Trials
Figure 9.6 Heat Map Analysis: Analysis by Popular Biomarkers and Trial Phase
Figure 9.7 Word Cloud Analysis: Popular and Emerging Biomarkers
Figure 9.8 Leading Players: Distribution by Number of Registered Trials
Figure 9.9 Heat Map Analysis: Distribution by Popular Biomarkers and Leading Industry Players
Figure 9.10 Heat Map Analysis: Distribution by Popular Biomarkers and Leading Non-industry Players
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Distribution by Publication Year
Figure 10.3 Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
Figure 10.4 Patent Analysis: Distribution by CPC Symbols
Figure 10.5 Patent Analysis: Emerging Focus Areas
Figure 10.6 Patent Analysis: Cumulative Distribution by Type of Organization
Figure 10.7 Patent Analysis: Leading Industry Players
Figure 10.8 Patent Analysis: Leading Non-Industry Players
Figure 10.9 Patent Analysis: Leading Individual Assignees
Figure 10.10 Patent Analysis (Industry Players): Benchmarking by Patent Characteristics
Figure 10.11 Patent Analysis: Distribution of Patents by Age
Figure 10.12 Non-Invasive Diagnostics for Fibrotic Diseases: Patent Valuation
Figure 11.1 Global Non-Invasive Diagnostics for Fibrotic Diseases Market, 2020-2030 (USD Million)
Figure 11.2 Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by Target Fibrotic Disease, 2025 and 2030
Figure 11.3 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Cystic Fibrosis, 2020-2030 (USD Million)
Figure 11.4 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Liver Fibrosis, 2020-2030 (USD Million)
Figure 11.5 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Pulmonary Fibrosis, 2020-2030 (USD Million)
Figure 11.6 Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by End Users, 2025 and 2030
Figure 11.7 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Hospitals and Clinics 2020-2030 (USD Million)
Figure 11.8 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Research Institutes 2020-2030 (USD Million)
Figure 11.9 Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by Region, 2025 and 2030
Figure 11.10 Non-Invasive Diagnostics for Fibrotic Diseases Market in North America, 2020- 2030 (USD Million)
Figure 11.11 Non-Invasive Diagnostics for Fibrotic Diseases Market in Europe, 2020-2030 (USD Million)
Figure 11.12 Non-Invasive Diagnostics for Fibrotic Diseases Market in Asia Pacific, 2020-2030 (USD Million)
Figure 11.13 Non-Invasive Diagnostics for Fibrotic Diseases Market in Latin America, 2020-2030 (USD Million)
Figure 11.14 Non-Invasive Diagnostics for Fibrotic Diseases Market in Middle East and North Africa, 2020-2030 (USD Million)

List Of Tables

Table 3.1 Cost of Biopsy of Different Organs (in USD)
Table 4.1 List of Biomarkers for Fibrotic Diseases
Table 5.1 List of Non-Invasive Diagnostics for Fibrotic Diseases
Table 5.2 Non-Invasive Diagnostics for Fibrotic Diseases: List of Product Developers
Table 6.1 Non-Invasive Diagnostics for Fibrotic Diseases: List of Companies Profiled
Table 6.2 Product Profile: FibroTest®
Table 6.3 Product Profile: ActiTest®
Table 6.4 Product Profile: NashTest®
Table 6.5 BioPredictive: Recent Developments and Future Outlook
Table 6.6 Product Profile: FIBROSCAN® 530 COMPACT
Table 6.7 Product Profile: FIBROSCAN® 430 MINI
Table 6.8 Product Profile: FIBROSCAN® 502 TOUCH
Table 6.9 Product Profile: FibroMeter™
Table 6.10 Echosens: Recent Developments and Future Outlook
Table 6.11 Product Profile: Macroduct® Sweat Collection System
Table 6.12 Product Profile: Sweat-Chek™ Analyzer
Table 6.13 Product Profile: Nanoduct® Neonatal Sweat Analysis System
Table 6.14 Product Profile: ChloroChek® Chloridometer®
Table 6.15 ELITechGroup: Recent Developments and Future Outlook
Table 6.16 Product Profile: TAEUS™
Table 6.17 Product Profile: LIVERFASt™
Table 6.18 Product Profile: LIVERFACt
Table 6.19 Product Profile: SteatoTEST
Table 6.20 Product Profile: LIVERFASt Select
Table 6.21 Product Profile: HealthFACTR
Table 6.22 Fibronotics: Recent Developments and Future Outlook
Table 6.23 Product Profile: INNO-LIPA® CFTR Deletions+6
Table 6.24 Product Profile: INNO-LiPA® CFTR iage
Table 6.25 Product Profile: INNO-LiPA® CFTR 17+Tn Update
Table 6.26 Product Profile: INNO-LiPA® CFTR 19
Table 6.27 Product Profile: INNO-LiPA® CFTR Italian Regional
Table 6.28 Product Profile: INNO-LiPA® CFTR Extra
Table 6.29 Product Profile: LiRAS® for LiPA® Cystic Fibrosis
Table 6.30 Product Profile: CFTR Sequencing and Deletion/Duplication Analysis
Table 6.31 Fujirebio: Recent Developments and Future Outlook
Table 6.32 Product Profile: CF Basic Carrier Screen
Table 6.33 Product Profile: Expanded CF Carrier Screen
Table 6.34 Product Profile: Cystic Fibrosis Poly T Analysis
Table 6.35 GenPath Diagnostics: Recent Developments and Future Outlook
Table 6.36 Product Profile: HepQuant® SHUNT
Table 6.37 Product Profile: HepQuant® FLOW
Table 6.38 Product Profile: HepQuant® STAT
Table 6.39 HepQuant: Recent Developments and Future Outlook
Table 6.40 Product Profile: NASH FibroSure®
Table 6.41 Product Profile: ASH FibroSure®
Table 6.42 Product Profile: Hepatitis C Virus (HCV) FibroSure®
Table 6.43 LabCorp: Recent Developments and Future Outlook
Table 6.44 Product Profile: xTAG® CF39v2 Kit
Table 6.45 Product Profile: xTAG® CF60v2 Kit
Table 6.46 Product Profile: xTAG® CF71v2 Kit
Table 6.47 Product Profile: Verigene CFTR and Verigene CFTR PolyT Nucleic Acid Tests
Table 6.48 Product Profile: MultiCode-PLx System
Table 6.49 Product Profile: INTROL® CF Panel III Control
Table 6.50 Luminex: Recent Developments and Future Outlook
Table 6.51 Product Profile: CF StripAssay® GER
Table 6.52 Product Profile: CF StripAssay® TUR
Table 6.53 Product Profile: CF StripAssay®
Table 6.54 Oasis Diagnostics: Recent Developments and Future Outlook
Table 6.55 Product Profile: GSP® Neonatal IRT kit
Table 6.56 Product Profile: AutoDELFIA® Neonatal IRT kit
Table 6.57 Product Profile: DELFIA® Neonatal IRT kit
Table 6.58 Product Profile: StepOne Newborn Screening Panel
Table 6.59 PerkinElmer: Recent Developments and Future Outlook
Table 6.60 Product Profile: EU2v1
Table 6.61 Product Profile: CF4v2
Table 6.62 Product Profile: CF30v2
Table 6.63 Yourgene Health: Recent Developments and Future Outlook
Table 7.1 Non-Invasive Diagnostics for Fibrotic Diseases: List of Partnerships and Collaborations
Table 12.1 Non-Invasive Diagnostics for Fibrotic Diseases: Summary of the Competitive Insights
Table 13.1 Biorion: Key Highlights
Table 13.2 Glycotest: Key Highlights
Table 13.3 Repeat Diagnostics: Key Highlights
Table 14.1 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Status of Development
Table 14.2 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Type of Product
Table 14.3 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Application Area
Table 14.4 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Target Fibrotic Disease
Table 14.5 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Type of Product and Target Fibrotic Disease
Table 14.6 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Type of Sample
Table 14.7 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Type of Biomarker
Table 14.8 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Turnaround Time
Table 14.9 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Requirement of Medical Assistance
Table 14.10 Product Developers: Distribution by Year of Establishment
Table 14.11 Product Developers: Distribution by Company Size
Table 14.12 Product Developers: Distribution by Geographical Location
Table 14.13 Leading Players: Distribution by Number of Products
Table 14.14 BioPredictive: Annual Revenues, 2016-2019 (USD Billion)
Table 14.15 Echosens: Annual Revenues, 2016-2019 (USD Billion)
Table 14.16 ELITechGroup: Annual Revenues, 2016-2019 (USD Billion)
Table 14.17 Fibronotics: Annual Revenues, 2016-2019 (USD Billion)
Table 14.18 Fujirebio: Annual Revenues, 2016-2019 (USD Billion)
Table 14.19 GenPath Diagnostics: Annual Revenues, 2016-2019 (USD Billion)
Table 14.20 HepQuant: Annual Revenues, 2016-2019 (USD Billion)
Table 14.21 LabCorp: Annual Revenues, 2016-2019 (USD Billion)
Table 14.22 Luminex: Annual Revenues, 2016-2020 (USD Billion)
Table 14.23 Oasis Diagnostics: Annual Revenues, 2016-2019 (USD Billion)
Table 14.24 PerkinElmer: Annual Revenues, 2016-2019 (USD Billion)
Table 14.25 Yourgene Health: Annual Revenues, 2016-2019 (USD Billion)
Table 14.26 Partnerships and Collaborations: Distribution by Year of Partnership
Table 14.27 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.28 Partnerships and Collaborations: Distribution by Type of Product
Table 14.29 Most Popular Products: Distribution by Number of Partnerships
Table 14.30 Partnerships and Collaborations: Distribution by Target Fibrotic Disease
Table 14.31 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 14.32 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 14.33 Most Active Players: Distribution by Number of Partnerships
Table 14.34 Partnerships and Collaborations: Regional Analysis
Table 14.35 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 14.36 Clinical Trial Analysis: Distribution by Trial Status
Table 14.37 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2020 (till June)
Table 14.38 Clinical Trial Analysis: Cumulative Year-wise Trend in Number of Patients Enrolled, Pre-2010-2020 (till June)
Table 14.39 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 14.40 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, Pre-2002-2020 (till June)
Table 14.41 Clinical Trial Analysis: Distribution by Study Design
Table 14.42 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 14.43 Leading Players: Analysis by Number of Trials
Table 14.44 Popular Product(s): Distribution by Number of Registered Trials
Table 14.45 Biomarker Analysis for Liver Fibrosis: Distribution by Type of Biomarker
Table 14.46 Biomarker Analysis for Liver Fibrosis: Distribution by Trial Phase and Type of Biomarker
Table 14.47 Biomarker Analysis for Liver Fibrosis: Distribution by Type of Liver Fibros
Table 14.48 Popular Biomarkers: Distribution by Number of Registered Trials
Table 14.49 Leading Players: Distribution by Number of Registered Trials
Table 14.50 Patent Analysis: Distribution by Type of Patent
Table 14.51 Patent Analysis: Distribution by Publication Year
Table 14.52 Patent Analysis: Distribution by Issuing Authority / Patent Offices Involve
Table 14.53 Patent Analysis: Distribution by CPC Symbols
Table 14.54 Patent Analysis: Cumulative Distribution by Type of Organization
Table 14.55 Patent Analysis: Leading Industry Players
Table 14.56 Patent Analysis: Leading Non-Industry Players
Table 14.57 Patent Analysis: Leading Individual Assignees
Table 14.58 Patent Analysis (Industry Players): Benchmarking by Patent Characteristics
Table 14.59 Patent Analysis: Distribution of Patents by Age
Table 14.60 Non-Invasive Diagnostics for Fibrotic Diseases: Patent Valuation
Table 14.61 Global Non-Invasive Diagnostics for Fibrotic Diseases Market, 2020-2030 (USD Million)
Table 14.62 Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by Indication, 2025 and 2030
Table 14.63 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Cystic Fibrosis, 2020-2030 (USD Million)
Table 14.64 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Liver Fibrosis, 2020-2030 (USD Million)
Table 14.65 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Pulmonary Fibrosis, 2020-2030 (USD Million)
Table 14.66 Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by End Users, 2025 and 2030
Table 14.67 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Hospitals and Clinics 2020-2030 (USD Million)
Table 14.68 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Research Institutes 2020-2030 (USD Million)
Table 14.69 Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by Region, 2025 and 2030
Table 14.70 Non-Invasive Diagnostics for Fibrotic Diseases Market in North America, 2020-2030 (USD Million)
Table 14.71 Non-Invasive Diagnostics for Fibrotic Diseases Market in Europe, 2020-2030 (USD Million)
Table 14.72 Non-Invasive Diagnostics for Fibrotic Diseases Market in Asia Pacific, 2020-2030 (USD Million)
Table 14.73 Non-Invasive Diagnostics for Fibrotic Diseases Market in Middle East and North Africa, 2020-2030 (USD Million)

Listed Companies

  1. 3T Radiology & Research
  2. 4DMedical
  3. A2F-Associates
  4. Aarhus University
  5. Ain Shams University
  6. Alpha Bioresearch
  7. AmCad BioMed
  8. Applera
  9. Arrowhead Pharmaceuticals
  10. Asan Medical Center
  11. Asian Institute of Gastroenterology
  12. Asper Biogene
  13. Assistance publique - Hôpitaux de Paris
  14. Assiut University
  15. Asuragen
  16. aTyr Pharma
  17. AutoGenomics
  18. Avisa Pharma
  19. Axcella Health
  20. Azienda Ospedaliera di Padova
  21. Beijing Friendship Hospital
  22. Beth Israel Deaconess Medical Center
  23. BILHI Genetics
  24. BillionToOne
  25. bioMérieux
  26. BioPredictive
  27. BiOrion Technologies
  28. Boehringer Ingelheim
  29. Bristol-Myers Squibb
  30. Broad Institute
  31. Celera
  32. Chang Gung Memorial Hospital
  33. Changhai Hospital
  34. Children's Hospital of Philadelphia
  35. Chung-Ang University
  36. CIC bioGUNE
  37. Cincinnati Children's Hospital Medical Center
  38. Cisbio
  39. Clinical Investigation Centre for Innovative Technology network 
  40. Clinical Micro Sensors
  41. Cliniques universitaires Saint-Luc
  42. Columbia University
  43. Congenica
  44. Corcept Therapeutics
  45. Credora Life Sciences
  46. Cystic Fibrosis Foundation
  47. Devyser
  48. Echosens
  49. Eli Lilly
  50. ELITechGroup
  51. Elucigene Diagnostics
  52. Eluthia
  53. Enanta Pharmaceuticals
  54. ENDRA Life Sciences
  55. ENYO Pharma 
  56. EUROIMMUN Medical Laboratory Diagnostics
  57. European Molecular Biology Laboratory (EMBL)
  58. Exalenz Bioscience
  59. FDNA
  60. Fibronostics
  61. Fujirebio
  62. Galectin Therapeutics
  63. GE Healthcare
  64. Geisinger Medical Center
  65. GeneDx
  66. GENFIT
  67. GenMark Diagnostics
  68. Genomax Technologies
  69. Genomic Diagnostics
  70. GenPath Diagnostics
  71. Georges Pompidou European Hospital
  72. Georgetown University
  73. Georgia State University
  74. Gilead Sciences
  75. GlycoBiomarker Leading Innovation
  76. Glycotest
  77. Goethe University
  78. Graz University of Technology
  79. Grenoble Alpes University Hospital
  80. Group K Diagnostics
  81. Hacettepe University
  82. HaEmek Medical Center
  83. Hangzhou Proprium Biotech 
  84. Hanyang University
  85. Harvard University
  86. Heidelberg University 
  87. Helena Biosciences
  88. HepQuant
  89. Hitachi Healthcare
  90. Hologic
  91. Hospices Civils de Lyon
  92. Hospital of South West Jutland
  93. HTG Molecular Diagnostics
  94. IBL International
  95. Illumina
  96. Imperial College London
  97. Indiana University
  98. Inje University
  99. Inselspital
  100. Invitae
  101. Johannes Gutenberg University Mainz
  102. Johns Hopkins University
  103. Kaohsiung Medical University Chung-Ho
  104. Karolinska Institutet
  105. Karolinska University Hospital
  106. Keimyung University Dongsan Medical Center
  107. Kiel University 
  108. King's College Hospital
  109. Konkuk University Hospital
  110. Korea University
  111. LabCorp
  112. Laboratorios Rubió 
  113. Laval University
  114. LCM Genect
  115. Leeds Teaching Hospitals NHS Trust
  116. Lille University Hospital
  117. Luminex
  118. Maastricht University Medical Center
  119. Mack Biotech
  120. MacroGenics
  121. Madrigal Pharmaceuticals
  122. Maine Molecular Quality Controls
  123. Manchester University NHS Foundation Trust
  124. Massachusetts General Hospital
  125. Massachusetts Institute of Technology
  126. Mayo Clinic
  127. Medical University of Graz
  128. Medical University of Vienna
  129. MetaPhy Health
  130. Milton S. Hershey Medical Center
  131. Nanfang Hospital of Southern Medical University
  132. Nanogen Biopharmaceutical
  133. Nantes University Hospital
  134. NASHNET
  135. Natera
  136. National Cancer Institute (NCI)
  137. National Heart, Lung, and Blood Institute (NHLBI)
  138. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  139. National Institutes of Health (NIH)
  140. National Nutrition and Food Technology Research Institute
  141. Navigene Genetic Science
  142. NGM Biopharmaceuticals
  143. Nordic Bioscience 
  144. Novartis
  145. Novo Nordisk
  146. NuvoAir
  147. Oasis Diagnostics
  148. Odense University Hospital
  149. Olympus Corporation of the Americas
  150. OWL Metabolomics
  151. patientMpower
  152. PerkinElmer
  153. Perspectum Diagnostics
  154. Pfizer
  155. Precision MedCare
  156. Promethus Biosciences
  157. ProPath
  158. Puerta de Hierro University Hospital
  159. Qilu Hospital of Shandong University
  160. Quest Diagnostics
  161. Quidel
  162. Ravgen
  163. Repeat Diagnostics
  164. Roche
  165. Royal Brompton & Harefield NHS Foundation Trust
  166. Ruijin Hospital
  167. RWTH Aachen University
  168. Samsung Medical Center
  169. Seoul National University Hospital
  170. Sequenom
  171. Servicio Madrileño de Salud 
  172. Severance Hospital
  173. Shanghai Zhongshan Hospital
  174. Shuguang Hospital
  175. Siemens Healthineers
  176. Sonic Incytes
  177. Soonchunhyang University Hospital
  178. SOPHiA GENETICS
  179. Southern Cross Diagnostics
  180. Stanford University
  181. Sun Yat-sen University
  182. SuperSonic Imagine 
  183. Sutter Health
  184. Svendborg Municipality Alcohol Rehabilitation Unit
  185. SYNLAB
  186. Sysmex
  187. Tanta University
  188. Terns Pharmaceuticals
  189. The Biomedical Research Foundation
  190. The Catholic University of Korea
  191. The Chinese University of Hong Kong
  192. The First Affiliated Hospital of Soochow University
  193. The Hospital for Sick Children (HSC)
  194. The National Pancreas Foundation
  195. The Oxford Dental College 
  196. The Sapienza University of Rome
  197. Thermo Fisher Scientific
  198. Third Wave Technology
  199. University College London
  200. University Hospital Angers
  201. University Hospital Frankfurt 
  202. University Hospital of Tours (CHUT)
  203. University of Bern
  204. University of Brighton
  205. University of California
  206. University of Copenhagen
  207. University of Florida
  208. University of Liège
  209. University of Lisbon
  210. University of Mannheim
  211. University of Michigan
  212. University of Minnesota
  213. University of New Mexico
  214. University of Oslo
  215. University of Pennsylvania
  216. University of Pittsburgh
  217. University of Southern Denmark
  218. University of Washington
  219. VA Connecticut Healthcare System
  220. Veracyte
  221. Virginia Commonwealth University
  222. Vitalograph
  223. VLVbio
  224. VolitionRX
  225. Wuhan Union Hospital
  226. Wuxi Hisky Medical Technologies
  227. Xi'an Jiaotong University
  228. Yale University
  229. Yangpu Hospital of Tongji University
  230. Yaqrit
  231. Yourgene Health

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.